Gelonghui May 14 丨 Hehuang Pharmaceutical (00013freedepositcasino.HK) today announced the launch of a HMPL-306 treatment in China for patients with isocitrate dehydrogenase ("IDH")1 or 2 mutationsfreedepositcasinoRelapsed/refractory acute myeloid leukemia (AML)freedepositcasinoRegistered Phase III clinical trial. The first subject received the first dose on May 11, 2024.